How to Find the Right Cell & Gene Therapy CDMO

Cell and gene therapy manufacturing can be difficult to reduce to a simple CDMO category.

A company may work broadly in advanced therapies while specializing in a specific technology, manufacturing process, vector type, or development stage.

That means the phrase cell and gene therapy CDMO is useful for discovery, but not enough for selection.

The sourcing process should quickly become more specific:

What exactly is being manufactured, and what does this program require from the manufacturing partner?

A cell and gene therapy CDMO provides development or manufacturing services for advanced therapy programs.

Depending on the organization, capabilities may include areas such as:

• cell processing
• viral vector development
• viral vector manufacturing
• plasmid DNA manufacturing
• process development
• analytical development
• technology transfer
• GMP manufacturing
• cryopreservation
• fill finish
• testing
• clinical supply support

Not every cell and gene therapy CDMO provides all of these services.

Specialization is common.

It is useful to group cell and gene therapy together at a high level, but the manufacturing requirements can differ substantially.

A cell therapy program may involve processing living cells.

A gene therapy program may depend on manufacturing a viral vector or another delivery system.

Some programs involve both.

The sponsor should therefore narrow the category early rather than treating every advanced-therapy CDMO as interchangeable.

Before comparing manufacturers, define the modality and manufacturing workflow as clearly as possible.

For cell therapy, that may involve distinctions such as:

• autologous vs. allogeneic
• cell type
• starting material
• expansion process
• genetic modification where applicable
• final product format

For gene therapy, the sponsor may need to define:

• vector type
• production platform
• upstream process
• downstream purification
• scale
• drug product requirements

These factors can dramatically change which facilities are relevant.

Autologous cell therapy manufacturing begins with material associated with an individual patient.

That creates operational demands around coordination, scheduling, and material identity.

Allogeneic therapies may use a different manufacturing model with larger production campaigns and inventory intended for multiple patients.

A manufacturer experienced with one model may not automatically be the preferred partner for the other.

Sponsors should investigate whether the CDMO's facility and operating model align with the therapy being developed.

For patient-specific products, maintaining correct identity and custody throughout the manufacturing process can be critical.

The sponsor may need to understand how the CDMO handles:

• receipt of starting material
• identification
• tracking
• manufacturing
• storage
• release
• shipment

These operational systems may be just as important as manufacturing equipment.

They should be investigated as part of the broader qualification process.

Many gene therapy programs depend on viral vectors.

Depending on the program, the sponsor may need to source manufacturing for vectors such as AAV or lentiviral vectors.

Vector manufacturing can involve its own:

• upstream process
• downstream purification
• analytics
• production scale
• equipment
• facility requirements

Some CDMOs provide vector manufacturing as part of a broader gene therapy offering.

Others specialize in it.

The sponsor should determine whether vector manufacturing and final therapy manufacturing should be sourced together or separately.

Some advanced-therapy manufacturing workflows require plasmid DNA as an important raw material or process input.

Sponsors may need to consider whether plasmid manufacturing is available internally at the CDMO, sourced separately, or provided through another supplier.

This can affect:

• project timing
• supply-chain coordination
• technical transfer
• regulatory documentation

A manufacturer should not be evaluated in isolation from critical upstream inputs.

Early cell and gene therapy programs may still have substantial process-development work ahead.

That can make development capability particularly important.

Sponsors may need support with areas such as:

• process optimization
• scale-up or scale-out
• culture conditions
• transduction
• purification
• formulation
• cryopreservation
• analytical methods

A manufacturing facility may have appropriate infrastructure but still be a poor fit if the development team cannot support the maturity of the sponsor's process.

Traditional manufacturing concepts of scale do not always translate neatly into cell and gene therapy.

Some programs scale by increasing batch size.

Others may require parallelization or scale-out.

The manufacturing strategy depends heavily on the modality and process.

Sponsors should therefore avoid comparing facilities only by a single “batch size” number.

The more useful question is whether the facility's production model aligns with the way the therapy needs to be manufactured.

Advanced therapies can require specialized analytical methods.

Depending on the product, manufacturers may need to support testing related to:

• identity
• potency
• purity
• viability
• vector characteristics
• residual impurities
• sterility
• release

Analytical development can become a major part of the manufacturing program.

The sponsor should understand whether required testing is performed internally or through external laboratories.

Advanced-therapy manufacturing can be highly facility-dependent.

Sponsors should investigate:

• the proposed manufacturing site
• manufacturing suites
• containment strategy
• segregation
• equipment
• scale
• cleanroom environment
• operational model

A parent company may operate several sites with very different capabilities.

The facility expected to support the project should therefore be part of the sourcing decision from the beginning.

An early clinical advanced-therapy program may need a partner willing to work with an evolving process.

A later-stage program may require greater emphasis on:

• process robustness
• comparability
• validation
• manufacturing consistency
• capacity
• supply reliability

A CDMO that works well for an exploratory program may not automatically be the right long-term manufacturing partner.

Selection criteria should reflect where the program is today.

Facility-level regulatory history should be included in appropriate preliminary diligence.

Available FDA Form 483 information may help sponsors identify issues that deserve additional investigation.

As with other modalities, regulatory documents should be interpreted in context.

Specialized advanced-therapy manufacturing capacity may be constrained by:

• facility availability
• cleanroom scheduling
• vector supply
• specialized equipment
• personnel
• testing
• raw materials

A technically relevant CDMO may still have a timeline that does not work for the program.

Sponsors should begin discussing realistic project kickoff and manufacturing availability once a facility appears technically suitable.

The shortlist should reflect the actual manufacturing program rather than the broad “cell and gene therapy” label.

Before building a shortlist, it helps to answer a few program-level questions:

• Is the product a cell therapy, a gene therapy, or a gene-modified cell therapy?
• Is the process autologous or allogeneic?
• Is a viral vector required, and will it be sourced separately?
• Where will plasmid DNA come from?
• How mature is the process, and what development support is needed?
• What scale and patient numbers does the next phase require?

Viral vector sourcing is covered in the viral vector CDMO guide, with deeper detail in the AAV CDMO guide and the lentiviral vector CDMO guide.

PCN helps cell and gene therapy sponsors compare manufacturing facilities on modality experience, capabilities, scale, and regulatory context, then request structured introductions so the CDMO can review the opportunity before deeper discussions begin.